[1] "DOXORUBICIN HYDROCHLORIDE - doxorubicin hydrochloride injection, solution" Pfizer Laboratories Div Pfizer Inc, LAB-0436-1.0, September 2011
[2] Pereira, G. et al, "Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to
Carvedilol", Current Pharmaceutical Design, 2011, 17, 2113-2129
[3] Timbrell, John: "Principles of Biochemical Toxicology", 4th Edition (Informa, 2009)
[4] Octavia, Y et al, "Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies", Journal of Molecular and Cellular Cardiology 52 (2012) 1213–1225
[5] S.T. Matalon et al., "Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta)", Reproductive Toxicology 18 (2004) 219–230
[6] Carvalho, C. et al. "Doxorubicin: The Good, the Bad and the Ugly Effect", Current Medicinal Chemistry, 2009, 16, 3267-3285
[7] Prados J, et al, Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy.” Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70.
[8] AG SCIENTIFIC: http://info.agscientific.com/blog/bid/150681/Doxorubicin-used-in-Cancer-Chemotherapy (19-05-2013)
[9] DRUG INFORMATION PORTAL: http://chem.sis.nlm.nih.gov/chemidplus/RenderImage?maxscale=30&width=300&height=300&superlistid=0023214928 (19-05-2013)
[10] Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drug in Health Care Settings, Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Publication number 2004-165, September 2004.
[11] NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012, Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Publication Number 2012-150 (Supersedes 2010–167), June 2012
[12] TOXNET: http://toxnet.nlm.nih.gov/ - Hazardous Substances Data Bank (HSDB) – Doxorrubicina (14/05/2013)
[13] INFARMED: Resumo das Características do Medicamento, Doxorrubicina Sandoz, Aprovado em 02-08-2010, Infarmed.